COMMUNIQUÉS West-GlobeNewswire

BioRestorative to Present a BRTX-100 Clinical Update at ISCT 2025
07/05/2025
MELVILLE, N.Y., May 07, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a clinical stage regenerative medicine innovator focused on stem cell-based [...]
GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
07/05/2025
Enrollment completed for the 6-week interim analysis with 24 of the 36 planned patients now enrolled Company on track to report interim biomarker data from the first 12 patients imminently Completion of patient [...]
Theriva Biologics Announces Pricing of $7.5 Million Public Offering
07/05/2025
ROCKVILLE, Md., May 07, 2025 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related [...]
Vistin Pharma ASA (VISTN): Update from the Election Committee
07/05/2025
Oslo, Norway, 07 May 2025 The Election Committee has received a request from Øystein Stray Spetalen that he does not want to be re-elected as a board member of Vistin Pharma ASA. The Election Committee has therefore [...]
ImmuneWalk Therapeutics Announces $7 Million Seed Financing and Upcoming Presentations of Positive Clinical Results at Upcoming Medical and Industry Conferences
07/05/2025
Completed seed financing round of $7 million from an institutional investor and ImmuneWalk’s management team Includes oral presentation of positive safety, pharmacokinetic, and pharmacodynamic data from immunology and [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
07/05/2025
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 7 May 2025 at 17.00 EEST Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
TerrAscend Closes on Ohio Dispensary Acquisition
07/05/2025
Transaction marks the Company’s entry into its sixth U.S. state Acquisition is expected to be immediately accretive on an EBITDA and cashflow basis TORONTO, May 07, 2025 (GLOBE NEWSWIRE) -- TerrAscend Corp. (“TerrAscend [...]
SeaStar Medical to Report First Quarter Financial Results on May 14, 2025
07/05/2025
DENVER, May 07, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and [...]
Oculis to Present at Upcoming May Investor Conferences
07/05/2025
ZUG, Switzerland, May 07, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases [...]
Oculis to Present at Upcoming May Investor Conferences
07/05/2025
ZUG, Switzerland, May 07, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases [...]
European Commission approves TREMFYA® (guselkumab), the first dual-acting IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn’s disease
07/05/2025
TREMFYA ® (guselkumab) induction therapy administered either intravenously (GALAXI 2 and 3) or subcutaneously (GRAVITI) achieved the co-primary endpoints of clinical remission a and endoscopic response b at Week 12 [...]
Isarna Therapeutics Presents Positive Phase 2 BETTER Trial Final Results at ARVO 2025
07/05/2025
Innovative antisense therapy blocking production of TGF-β2 shows promise in reducing retinal fibrosis and improving outcomes in patients with wet AMD and DME Gräfelfing, Germany, May 7 th , 2025 – Isarna Therapeutics [...]
Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech’s Product Revenues in 2025
07/05/2025
Alvotech (NASDAQ: ALVO) (the “Company”) a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today issued a statement on the anticipated impact of [...]
Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech’s Product Revenues in 2025
07/05/2025
REYKJAVIK, Iceland, May 07, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) (the “Company”) a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today [...]
LifeStance Reports First Quarter 2025 Results
07/05/2025
SCOTTSDALE, Ariz., May 07, 2025 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation’s largest providers of outpatient mental healthcare, today announced financial results for the first [...]
Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025
07/05/2025
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health [...]
Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting
07/05/2025
Codexis to showcase data that demonstrate the scalability and reproducibility of its enzymatic siRNA manufacturing processes Three CDMO presentations to feature data on performance of Codexis double-stranded RNA ligases [...]
Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results
07/05/2025
Generated $166.8 million in 1Q 2025 revenues, including $149.9 million in U.S. net product sales SYFOVRE ® (pegcetacoplan injection) injection demand grew 4% quarter-over-quarter, with U.S. net product revenue of $130.2 [...]
Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance
07/05/2025
-- Generated $52.5 million in net revenue from sales of LUMRYZ™, a 93% increase over the first quarter of 2024 -- -- 2,800 patients on LUMRYZ as of March 31, 2025, a net increase of 300 patients since December 31, 2024 [...]

Pages